MOTS-c vs SS-31 — mitochondrial peptides compared
MOTS-c and SS-31 are the two most-studied research peptides in the mitochondrial-function literature, but they operate by very different mechanisms. MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded within the mitochondrial 12S rRNA gene — it acts as a stress-response signalling molecule, modulating AMPK activity and improving glucose homeostasis and metabolic flexibility. SS-31 (elamipretide) is a synthetic 4-amino-acid mitochondria-targeted compound that selectively binds cardiolipin in the inner mitochondrial membrane, stabilising the electron transport chain. Both are mitochondrial, but MOTS-c is signalling-focused; SS-31 is structural-focused.
Side-by-side
| MOTS-c 40 mg | SS-31 (Elamipretide) | |
|---|---|---|
| Class | Mitochondrial-derived peptide (MDP) | Mitochondria-targeted synthetic peptide |
| Length | 16 amino acids | 4 amino acids |
| Mechanism | AMPK activation, metabolic signalling | Cardiolipin binding, ETC stabilisation |
| Origin | Encoded within mitochondrial 12S rRNA | Synthetic — Stealth Biotherapeutics |
| Research focus | Metabolic / age-related / glucose homeostasis | Cardiomyopathy, ophthalmic disease |
| Clinical stage | Pre-clinical / animal model | Phase 3 (Stealth Biotherapeutics) |
What to know
- ·MOTS-c is the headline 'mitochondrial signalling peptide' in longevity research — published by Pinchas Cohen's group at USC since 2015.
- ·SS-31 has the larger clinical-trial footprint — Stealth Biotherapeutics has run multiple phase 2 / 3 trials in cardiomyopathy and ophthalmic indications.
- ·Mechanisms are complementary, not competing — research-protocol literature occasionally pairs them for additive mitochondrial effects.
- ·MOTS-c levels decline with age in the literature; SS-31 has no endogenous counterpart.
- ·Both are research-use only.
Where the literature diverges
MOTS-c research is dominated by Cohen's Pinchas group at USC and a handful of metabolic-disease and exercise-physiology papers showing AMPK activation and improved insulin sensitivity in animal models. SS-31 / elamipretide research is industry-driven (Stealth Biotherapeutics) and clinical-trial-heavy, with primary endpoints around cardiomyopathy heart failure markers and Leber's Hereditary Optic Neuropathy. The two compounds occupy different stages of the evidence pipeline.
FAQ
Which is more developed clinically?+
SS-31 / elamipretide, by a wide margin — Stealth Biotherapeutics has a phase 3 programme. MOTS-c is essentially pre-clinical with growing observational/exercise-physiology research but no major industry-led clinical trials.
Are they interchangeable?+
No. The mechanisms are different — MOTS-c is upstream signalling (AMPK), SS-31 is downstream structural (cardiolipin/ETC). Research designs investigating the same biology would typically choose one or the other based on the specific question, not interchange them.
Why the longevity-research interest in MOTS-c?+
Endogenous MOTS-c levels decline with age in the literature, and exogenous administration in animal models has been associated with improved metabolic health and exercise performance. This pattern fits the longevity research framing of 'restoring a youthful signalling molecule.' Whether this translates to humans remains an open research question.
This is a research-context comparison of compound mechanism and published trial outcomes. Not medical advice. Both compounds are research-use only when sold by Omega Grade — for in vitro laboratory investigation, not human or veterinary administration.
- ResearchMOTS-c 40 mg
MOTS-c is a 16-residue peptide encoded in the mitochondrial 12S rRNA region. Described by the Cohen lab in 2015 — studied in metabolic and exercise bi
- ResearchNAD⁺ 500 mg kit
Nicotinamide adenine dinucleotide — the coenzyme central to cellular electron-transfer, sirtuin signalling, and redox biology.
- ResearchNAD⁺ 1000 mg pen
High-dose pen format NAD⁺ — double the 500 mg vial kit, in a pre-filled pen device.
- GlossaryAMPK
A cellular energy sensor — activated when ATP drops, promotes catabolic / energy-restoring pathways.
- BiomarkerTSH 4.5 mIU/L
TSH at 4.5 mIU/L sits at the top edge of most printed reference ranges (typically 0.4–4.0). What that number indicates physiologically, why "high-normal" matters, and what the research literature looks at when this pattern appears.
- BiomarkerHOMA-IR 2.5
HOMA-IR is a calculated index from fasting glucose × fasting insulin. A HOMA-IR of 2.5 sits at the threshold most metabolic research uses for early insulin resistance, often years before HbA1c shifts.